Bristol-Myers Squibb plans 113 job cuts in southern Indiana
Drugmaker Bristol-Myers Squibb Co. plans to close one of its southern Indiana facilities and cut jobs at another.
Health Care Businesses
Articles
Lilly reports $942 million profit in third quarter
Excluding special items, Eli Lilly and Co.’s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog
sales. Lilly’s revenue rose 7 percent in the quarter over the same period of 2008,
to $5.56 billion.
Medco plans to compare Plavix, Effient in study
Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world’s second-best selling drug, with
Effient, a potential blockbuster drug sold by Indianapolis-based Eli Lilly and Co.
Cook calls for new approach to health reform
Founder of medical device firm says Congress should fund network of low-cost clinics.
Endocyte receives $26M infusion from investors
West Lafayette-based Endocyte Inc. announced Friday that it has closed on $26 million in equity financing to help the company
continue developing cancer-fighting drugs.
Lilly to pay Idaho $13M in drug settlement
Idaho is getting $13 million as part of a settlement reached with Indianapolis-based Eli Lilly and Co. over its marketing of
anti-psychotic drug Zyprexa.
Lilly to sell Lafayette plant to German firm
Nearly 700 workers will be offered severance, new jobs
Baucus health reform bill would stick Indiana companies with fees
The health reform bill sponsored by U.S. Sen. Max Baucus, D-Mont., would help pay for expanded health insurance coverage
by levying fees of $13 billion a year on the health care industry. The fees would deliver a hefty bill to just
about all of Indiana’s major health care companies. But how they’re reacting to the fees is all over the map.
Lilly settles Zyprexa suit with S. Carolina
Eli Lilly and Co. has agreed to settle the State of South Carolina’s lawsuit that claimed Lilly improperly marketed the antipsychotic
drug Zyprexa, according to Bloomberg News.
Proposed Fishers medical park faces uncertain demand
Fishers development officials hope to create a huge cluster of medical and research facilities near Interstate 69’s Exit
10, near St. Vincent Medical Center Northeast, but local real estate experts disagree about the amount of potential demand
for such a development.
Connecticut gets $25 million from Zyprexa lawsuit
Connecticut officials say Eli Lilly and Co. has agreed to a $25 million settlement with the state over claims the drug maker
marketed its anti-psychotic drug, Zyprexa, for unapproved uses and harmed patients.
Lilly’s win in Evista patent case crucial, analyst says
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.’s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.
Judge upholds Lilly’s Evista patent
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced
late yesterday.
Lilly agrees to settle more state Zyprexa suits
Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally
marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.
Lilly sells constipation drug to Adolor
Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.
Mead Johnson plans expansion in Evansville
Mead Johnson Nutrition plans to spend nearly $33 million at a southwestern Indiana facility where it plans to start making
powdered infant formula products.
Lilly: Alimta improves lung-cancer survival time
Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.
Hill-Rom begins CEO search under succession plan
Medical equipment supplier Hill-Rom Holdings Inc. said yesterday it has begun a chief executive search to plan for the retirement
of current CEO Peter Soderberg.
UPDATE: Pipeline challenges force Lilly restructuring moves
Since John Lechleiter was named CEO 18 months ago, he’s bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today’s announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company’s business units ups the ante on that bet, while indicating that it isn’t working yet.
Lilly reorganization to cut 5,500 positions over 2 years
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.